Clinical Publications

Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. 

Transfusion. 2010 Sep;50(9):1980-7. doi: 10.1111/j.1537-2995.2010.02720.x.

Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy

J Pediatr. 2014 May;164(5):973-979.e1. doi: 10.1016/j.jpeds.2013.11.036. Epub 2013 Dec 31.

Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus

Pediatr Res. 2015 Dec;78(6):712-6. doi: 10.1038/pr.2015.161. Epub 2015 Sep 2.

Autologous Cord Blood Infusions are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial

Stem Cells Transl Med. 2017 May;6(5):1332-1339. doi: 10.1002/sctm.16-0474. Epub 2017 Apr 5.

Effects of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial

Stem Cells Transl Med. 2017 Dec;6(12):2071-2078. doi: 10.1002/sctm.17-0102. Epub 2017 Oct 28.


Research/Academic Publications

Preclinical Characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.

Cytotherapy. 2015 Jun;17(6):803-815. doi: 10.1016/j.jcyt.2015.02.006. Epub 2015 Mar 12.

A cord blood monocyte-derived cell therapy product accelerates brain remyelination

JCI Insight. 2016 Aug 18;1(13):e86667.

Gene products promoting remyelination are up-regulated in a cell therapy product manufactured from banked human cord blood

Cytotherapy. 2017 Jun;19(6):771-782. doi: 10.1016/j.jcyt.2017.03.004. Epub 2017 Apr 5.